Mosapride citrate dihydrate
Based on 6 publication(s) in Google Scholar
Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 636582-62-2
- Formula: C27H37ClFN3O12
- Molecular Weight:650.05
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Mosapride citrate dihydrate
MoreAll 5-HT Receptor Isoforms
More
Biological Activity
|
5-HT4 Receptor |
Kv4.3 15.2 μM (IC50) |
Mosapride (0.3-30 μM) exhibits an inhibitory activity against Kv4.3 with an IC50 of 15.2 μM in a concentration-dependent manner. Mosapride also inhibits the open state of Kv4.3 currents during depolarization and accelerates the closed-state inactivation at subthreshold potentials[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Beagle dogs[2]
-
Dosage:0.3-3 mg/kg
-
Administration:Intravenous injection; 0.3-3 mg/kg
-
Result:Increased the antral motor activity dose-dependently in conscious dogs.
Chemical Information
-
CAS No. 636582-62-2
-
Appearance Solid
-
Molecular Weight 650.05
-
Formula C27H37ClFN3O12
-
Color White to off-white
-
SMILES
O=C(NCC1CN(CC2=CC=C(F)C=C2)CCO1)C3=CC(Cl)=C(N)C=C3OCC.O=C(CC(C(O)=O)(O)CC(O)=O)O.O.O
-
Synonyms
TAK-370 citrate dihydrate; AS-4370 citrate dihydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
Yiqi Kaimi prescription regulates protein phosphorylation to promote intestinal motility in slow transit constipation. [Abstract]2024 Jul 15:329:118118. PMID: 38614261 -
Chin J Integr Med
Zhizhu Decoction Alleviates Intestinal Barrier Damage via Regulating SIRT1/FoxO1 Signaling Pathway in Slow Transit Constipation Model Mice. [Abstract]2023 Sep;29(9):809-817. PMID: 36044116 -
Dig Dis Sci
Kaempferol Ameliorates Functional Constipation in Mice by Regulating Autophagy of Interstitial Cells of Cajal via the p53/AMPK/mTOR Axis. [Abstract]2025 Nov 15. PMID: 41240265 -
J Appl Microbiol
Houpo Paiqi Mixture Promotes Intestinal Motility in Constipated Rats by Modulating Gut Microbiota and Activating 5-HT-cAMP-PKA Signal Pathway. [Abstract]2023 Aug 1;134(8):lxad153. PMID: 37481692 -
Drug Metab Pharmacokinet
2020 Feb;35(1):102-110. PMID: 31732429 -
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 2013;386(10):905-16. [Content Brief]
[2]. Mine Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. The Journal of pharmacology and experimental therapeutics. 1997;283(3):1000-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)